Hide metadata

dc.date.accessioned2020-07-09T18:38:51Z
dc.date.available2020-07-09T18:38:51Z
dc.date.created2020-02-16T23:22:06Z
dc.date.issued2016
dc.identifier.citationQadri, Dr Firdausi Wierzba, Thomas F. Ali, Mohammad Chowdhury, Fahima Khan, Ashraful Islam Saha, Amit Khan, Iqbal A. Asaduzzaman, Muhammad Akter, Afroza Khan, Arifuzzaman Begum, Yasmin A Bhuiyan, Taufiqur R Khanam, Farhana Chowdhury, Mohiul I. Islam, Taufiqul Chowdhury, Atique I. Rahman, Anisur Siddique, Shah A. You, Young A. Kim, Deok R. Siddik, Ashraf U. Saha, Nirod C. Kabir, Alamgir Cravioto, Alejandro Desai, Sachin N. Singh, Ajit P. Clemens, John D. . Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh. New England Journal of Medicine. 2016, 374, 1723-1732
dc.identifier.urihttp://hdl.handle.net/10852/77703
dc.description.abstractBACKGROUND A single-dose regimen of the current killed oral cholera vaccines that have been prequalified by the World Health Organization would make them more attractive for use against endemic and epidemic cholera. We conducted an efficacy trial of a single dose of the killed oral cholera vaccine Shanchol, which is currently given in a two-dose schedule, in an urban area in which cholera is highly endemic. METHODS Nonpregnant residents of Dhaka, Bangladesh, who were 1 year of age or older were randomly assigned to receive a single dose of oral cholera vaccine or oral placebo. The primary outcome was vaccine protective efficacy against culture-confirmed cholera occurring 7 to 180 days after dosing. Prespecified secondary outcomes included protective efficacy against severely dehydrating culture-confirmed cholera during the same interval, against cholera and severe cholera occurring 7 to 90 versus 91 to 180 days after dosing, and against cholera and severe cholera according to age at baseline. RESULTS A total of 101 episodes of cholera, 37 associated with severe dehydration, were detected among the 204,700 persons who received one dose of vaccine or placebo. The vaccine protective efficacy was 40% (95% confidence interval [CI], 11 to 60%; 0.37 cases per 1000 vaccine recipients vs. 0.62 cases per 1000 placebo recipients) against all cholera episodes, 63% (95% CI, 24 to 82%; 0.10 vs. 0.26 cases per 1000 recipients) against severely dehydrating cholera episodes, and 63% (95% CI, −39 to 90%), 56% (95% CI, 16 to 77%), and 16% (95% CI, −49% to 53%) against all cholera episodes among persons vaccinated at the age of 5 to 14 years, 15 or more years, and 1 to 4 years, respectively, although the differences according to age were not significant (P=0.25). Adverse events occurred at similar frequencies in the two groups. CONCLUSIONS A single dose of the oral cholera vaccine was efficacious in older children (≥5 years of age) and in adults in a setting with a high level of cholera endemicity.en_US
dc.languageEN
dc.titleEfficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladeshen_US
dc.typeJournal articleen_US
dc.creator.authorQadri, Dr Firdausi
dc.creator.authorWierzba, Thomas F.
dc.creator.authorAli, Mohammad
dc.creator.authorChowdhury, Fahima
dc.creator.authorKhan, Ashraful Islam
dc.creator.authorSaha, Amit
dc.creator.authorKhan, Iqbal A.
dc.creator.authorAsaduzzaman, Muhammad
dc.creator.authorAkter, Afroza
dc.creator.authorKhan, Arifuzzaman
dc.creator.authorBegum, Yasmin A
dc.creator.authorBhuiyan, Taufiqur R
dc.creator.authorKhanam, Farhana
dc.creator.authorChowdhury, Mohiul I.
dc.creator.authorIslam, Taufiqul
dc.creator.authorChowdhury, Atique I.
dc.creator.authorRahman, Anisur
dc.creator.authorSiddique, Shah A.
dc.creator.authorYou, Young A.
dc.creator.authorKim, Deok R.
dc.creator.authorSiddik, Ashraf U.
dc.creator.authorSaha, Nirod C.
dc.creator.authorKabir, Alamgir
dc.creator.authorCravioto, Alejandro
dc.creator.authorDesai, Sachin N.
dc.creator.authorSingh, Ajit P.
dc.creator.authorClemens, John D.
cristin.unitcode185,52,14,0
cristin.unitnameAvdeling for samfunnsmedisin og global helse
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin1794565
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=New England Journal of Medicine&rft.volume=374&rft.spage=1723&rft.date=2016
dc.identifier.jtitleNew England Journal of Medicine
dc.identifier.volume374
dc.identifier.issue18
dc.identifier.startpage1723
dc.identifier.endpage1732
dc.identifier.doihttps://doi.org/10.1056/NEJMoa1510330
dc.identifier.urnURN:NBN:no-80793
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn0028-4793
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/77703/2/nejmoa1510330.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata